X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA DR. REDDYS LAB ALEMBIC PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 29.0 29.9 97.0% View Chart
P/BV x 6.6 2.9 225.8% View Chart
Dividend Yield % 0.7 0.9 77.2%  

Financials

 ALEMBIC PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
DR. REDDYS LAB
Mar-17
ALEMBIC PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs7923,397 23.3%   
Low Rs4432,560 17.3%   
Sales per share (Unadj.) Rs167.0856.5 19.5%  
Earnings per share (Unadj.) Rs38.278.0 49.0%  
Cash flow per share (Unadj.) Rs42.0139.9 30.0%  
Dividends per share (Unadj.) Rs4.0020.00 20.0%  
Dividend yield (eoy) %0.60.7 96.5%  
Book value per share (Unadj.) Rs84.9739.8 11.5%  
Shares outstanding (eoy) m188.52165.74 113.7%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.73.5 106.3%   
Avg P/E ratio x16.238.2 42.3%  
P/CF ratio (eoy) x14.721.3 69.1%  
Price / Book Value ratio x7.34.0 180.6%  
Dividend payout %10.525.7 40.9%   
Avg Mkt Cap Rs m116,383493,632 23.6%   
No. of employees `000NA22.7 0.0%   
Total wages/salary Rs m4,21431,068 13.6%   
Avg. sales/employee Rs ThNM6,259.0-  
Avg. wages/employee Rs ThNM1,369.8-  
Avg. net profit/employee Rs ThNM569.7-  
INCOME DATA
Net Sales Rs m31,487141,961 22.2%  
Other income Rs m551,715 3.2%   
Total revenues Rs m31,542143,676 22.0%   
Gross profit Rs m10,06024,722 40.7%  
Depreciation Rs m72210,266 7.0%   
Interest Rs m37634 5.8%   
Profit before tax Rs m9,35615,537 60.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-2349 -0.4%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1602,965 72.9%   
Profit after tax Rs m7,19412,921 55.7%  
Gross profit margin %31.917.4 183.5%  
Effective tax rate %23.119.1 121.0%   
Net profit margin %22.89.1 251.0%  
BALANCE SHEET DATA
Current assets Rs m15,06696,837 15.6%   
Current liabilities Rs m7,67484,199 9.1%   
Net working cap to sales %23.58.9 263.7%  
Current ratio x2.01.2 170.7%  
Inventory Days Days6773 91.3%  
Debtors Days Days4198 41.6%  
Net fixed assets Rs m8,237102,552 8.0%   
Share capital Rs m377829 45.5%   
"Free" reserves Rs m15,416121,792 12.7%   
Net worth Rs m16,005122,621 13.1%   
Long term debt Rs m05,449 0.0%   
Total assets Rs m24,594218,165 11.3%  
Interest coverage x255.225.5 1,000.7%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.7 196.8%   
Return on assets %29.46.2 473.2%  
Return on equity %44.910.5 426.6%  
Return on capital %58.712.9 454.9%  
Exports to sales %55.754.6 102.1%   
Imports to sales %10.49.4 111.5%   
Exports (fob) Rs m17,55177,520 22.6%   
Imports (cif) Rs m3,28313,274 24.7%   
Fx inflow Rs m17,81181,670 21.8%   
Fx outflow Rs m5,31826,355 20.2%   
Net fx Rs m12,49355,315 22.6%   
CASH FLOW
From Operations Rs m9,30421,444 43.4%  
From Investments Rs m-3,105-18,404 16.9%  
From Financial Activity Rs m-1,959-3,692 53.1%  
Net Cashflow Rs m4,240-1,144 -370.6%  

Share Holding

Indian Promoters % 74.1 25.5 290.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 5.4 53.7%  
FIIs % 9.1 35.3 25.8%  
ADR/GDR % 0.0 18.5 -  
Free float % 13.9 15.3 90.8%  
Shareholders   49,328 75,885 65.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SHASUN PHARMA  CIPLA  TORRENT PHARMA  ALEMBIC LTD  WYETH LTD  

Compare ALEMBIC PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - FULFORD INDIA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS